Jump Financial, LLC Tg Therapeutics, Inc. Transaction History

Jump Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$17.21 - $25.28 $5.32 Million - $7.81 Million	-309,004 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $4.12 Million - $5.93 Million	309,004 New	309,004 $5.5 Million
Q3 2023 Oct 21, 2024	BUY	$8.36 - $26.5 $3.06 Million - $9.7 Million	366,012 Added 342.2%	472,972 $3.95 Million
Q3 2023 Nov 07, 2023	BUY	$8.36 - $26.5 $3.06 Million - $9.7 Million	366,012 Added 342.2%	472,972 $3.95 Million
Q2 2023 Oct 21, 2024	SELL	$15.48 - $35.0 $3.13 Million - $7.07 Million	-202,044 Reduced 65.39%	106,960 $2.66 Million
Q2 2023 Aug 07, 2023	BUY	$15.48 - $35.0 $1.66 Million - $3.74 Million	106,960 New	106,960 $2.66 Million
Q2 2022 Aug 09, 2022	SELL	$3.74 - $10.66 $429,352 - $1.22 Million	-114,800 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$7.81 - $20.45 $896,588 - $2.35 Million	114,800 New	114,800 $1.09 Million
Q1 2021 May 17, 2021	SELL	$41.61 - $54.3 $962,980 - $1.26 Million	-23,143 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$25.27 - $54.9 $584,823 - $1.27 Million	23,143 New	23,143 $1.2 Million

339

88.5M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $5B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.